High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer.

Erkan TopkanAhmet KucukEmine Elif OzkanDuriye OzturkAli Ayberk BesenHuseyin MertsoyluBerrin PehlivanUgur Selek

Published in: Discover. Oncology (2023)

The findings of this hypothesis-generating retrospective analysis claimed that the novel PIV was an independent and steadfast predictor of PFS and OS in stage IIIB/C NSCLC patients.

Keyphrases

end stage renal disease
small cell lung cancer
ejection fraction
newly diagnosed
chronic kidney disease
oxidative stress
prognostic factors
patient reported outcomes
squamous cell carcinoma
adipose tissue
skeletal muscle
epidermal growth factor receptor